I now have all the material needed to compile detailed, comprehensive biochemistry notes. Let me write the full answer.
Digestion and Absorption of Fat - Detailed Biochemistry Notes
1. Overview of Dietary Lipids
The average daily intake of lipids is approximately 78 g, of which:
- >90% is triacylglycerol (TAG/triglyceride) - three fatty acids esterified to a glycerol backbone
- Remainder: cholesterol, cholesteryl esters, phospholipids, and free fatty acids (FFA)
Digestion of dietary lipids begins in the stomach and is completed in the small intestine.
2. Step 1 - Emulsification
Why emulsification is needed: Dietary fats are hydrophobic. Digestive enzymes work at the oil-water interface. Increasing surface area dramatically increases the rate of enzymatic hydrolysis.
Mechanical Emulsification
- Begins during food preparation (grinding, cooking, marinating)
- Continued by chewing and gastric churning (antral peristalsis against a closed pylorus)
- Gastric contents squirt intermittently into the duodenum
- Intestinal peristalsis mixes contents with pancreatic and biliary secretions
Chemical Emulsification (in the duodenum)
- Bile salts (made in liver, stored in gallbladder) are amphipathic derivatives of cholesterol. Conjugated bile salts consist of a hydroxylated sterol ring with a side chain covalently attached to glycine or taurine by an amide bond.
- Bile salts interact with lipid droplets and the aqueous environment, stabilizing droplets and preventing coalescence.
- Phosphatidylcholine from bile also acts as an emulsifier.
- Products of early digestion (fatty acids, monoglycerides) themselves act as additional emulsifiers.
- The emulsion droplet surface is coated with membrane lipids, denatured proteins, and biliary phospholipids/cholesterol. The polar heads project into the water; the charges prevent coalescence.
Medical Physiology (Boron & Boulpaep), p. 1377
3. Step 2 - Enzymatic Digestion
A. Gastric Phase (Limited)
| Enzyme | Source | Optimal pH | Substrates |
|---|
| Lingual lipase | Ebner glands (tongue) | 4-6 | TAG, especially short/medium chain FA |
| Gastric lipase | Gastric chief cells (mucosa) | 4-6 | TAG - preferentially at sn-3 position |
- Gastric lipase is a 42-kDa glycoprotein stimulated by gastrin
- Both are acid lipases - important in neonates (pancreatic lipase not yet established) and pancreatic insufficiency
- Gastric lipase can hydrolyze ~20-33% of dietary fat in pancreatic insufficiency
- Products (particularly short/medium-chain FAs) signal more distal GI tract to release CCK
Lippincott Illustrated Reviews: Biochemistry 8e, p. 494; Ganong's Physiology 26e
B. Duodenal / Pancreatic Phase (Major)
Hormonally regulated via CCK (from I-cells of duodenum) and secretin, which stimulate secretion of pancreatic juice.
1. Pancreatic Lipase (Triacylglycerol Lipase)
- Most important enzyme for fat digestion
- Constitutes 2-3% of total pancreatic protein - extremely abundant
- Preferentially cleaves FA at positions 1 and 3 of TAG
- Primary products: 2-monoacylglycerol (2-MAG) + 2 free fatty acids
- The sn-2 bond is hydrolyzed slowly - 2-MAG remains largely intact
- Requires the oil-water interface (acts on emulsified fat)
- Inhibited by bile salts (which coat the droplet surface) unless colipase is present
2. Colipase
- Co-secreted by the pancreas as the zymogen procolipase
- Activated in the intestinal lumen by trypsin
- Binds lipase in a 1:1 ratio, anchoring it at the lipid-aqueous interface
- Overcomes inhibition by bile salts - allows lipase to remain associated with lipid droplets even in the presence of bile acids
3. Cholesterol Ester Hydrolase (Cholesterol Esterase)
- ~4% of total protein in pancreatic juice
- Hydrolyzes cholesterol esters → cholesterol + FFA
- Also cleaves esters of fat-soluble vitamins (A, D, E, K) and phospholipids, and TAG
- Activity greatly enhanced in the presence of bile salts
- A very similar enzyme is found in human milk
4. Phospholipase A2 (PLA2)
- Secreted as the proenzyme (zymogen), activated by trypsin in the intestinal lumen
- Requires bile salts for optimal activity
- Removes FA from carbon 2 of phospholipids → lysophospholipid + FFA
- Phosphatidylcholine → lysophosphatidylcholine
- Remaining FA at carbon 1 can be removed by lysophospholipase → glycerylphosphoryl base (e.g., glycerylphosphorylcholine)
Lippincott Illustrated Reviews: Biochemistry 8e, p. 497
Summary of Pancreatic Products:
| Substrate | Enzyme | Products |
|---|
| TAG | Pancreatic lipase + colipase | 2-MAG + 2 FFA |
| Cholesterol esters | Cholesterol esterase | Cholesterol + FFA |
| Phospholipids | PLA2 | Lysophospholipid + FFA |
4. Step 3 - Micelle Formation
After lipolysis, the products of digestion (2-MAG, FFA, cholesterol, lysophospholipids) interact with bile salts to form mixed micelles.
How Micelles Form
- Lipolytic products build up in the surface of the emulsion droplet
- A multilamellar liquid crystalline layer forms and buds off as multilamellar vesicles (MLVs)
- Bile-salt micelles transform MLVs into unilamellar vesicles
- Further transformation into mixed micelles
Mixed Micelle Structure
- Cylindrical aggregates of bile salts + mixed lipids
- Hydrophobic center contains: FFA, 2-MAG, cholesterol, fat-soluble vitamins
- Hydrophilic exterior faces the aqueous phase
- Diameter: 3-10 nm (much smaller than emulsion droplets)
Why Micelles Are Important
- Further solubilize the hydrophobic lipids
- Provide a transport mechanism through the unstirred water layer (UWL) to the brush border of enterocytes
- Micelles move down their concentration gradient through the UWL
- Lipids diffuse out of micelles at the brush border - a saturated aqueous solution of lipids is maintained in contact with the enterocyte surface
Ganong's Review of Medical Physiology 26e, p. 485; Medical Physiology (Boron), p. 1381
5. Step 4 - Uptake by Enterocytes
Short- and Medium-Chain Fatty Acids (SCFA/MCFA, ≤12 carbons)
- Water-soluble enough at intestinal pH
- Do NOT require incorporation into micelles
- Absorbed directly by simple diffusion into the enterocyte
- Pass directly into the portal blood (not lymph) bound to albumin
- Transported to the liver via the portal vein
- Do NOT require chylomicron formation
Long-Chain Fatty Acids (LCFA, >12 carbons)
- Poorly soluble in water at physiological pH
- Must be incorporated into micelles for transport
- Uptake at the brush border: by a combination of passive diffusion and facilitated transport (via fatty acid transport proteins - FATP, FAT/CD36)
- Once inside the enterocyte, are bound by fatty acid-binding proteins (FABPs)
Cholesterol Absorption
- Free cholesterol diffuses from micelles into enterocytes
- Mediated partly by NPC1L1 (Niemann-Pick C1-Like 1) transporter - the target of ezetimibe
- ~50% of dietary cholesterol is absorbed
Fat-Soluble Vitamins (A, D, E, K)
- Absorbed from micelles along with LCFA and 2-MAG
- Deficiency occurs when bile salts or pancreatic enzymes are absent (e.g., common bile duct obstruction, pancreatic insufficiency)
6. Step 5 - Intracellular Processing (Re-esterification)
Inside the enterocyte smooth endoplasmic reticulum (SER), absorbed lipids are re-esterified:
TAG Re-synthesis (Monoglyceride Pathway - predominant in intestine)
Step 1: Long-chain FA are activated to fatty acyl-CoA by:
FFA + CoA + ATP → Fatty acyl-CoA + AMP + PPi
Enzyme: Fatty acyl-CoA synthetase (Thiokinase)
Step 2: 2-MAG + Fatty acyl-CoA → Diacylglycerol (DAG)
Enzyme: Acyl-CoA:monoacylglycerol acyltransferase (MGAT)
Step 3: DAG + Fatty acyl-CoA → Triacylglycerol (TAG)
Enzyme: Acyl-CoA:diacylglycerol acyltransferase (DGAT)
Cholesterol Re-esterification
Cholesterol + Fatty acyl-CoA → Cholesteryl ester
Enzyme: Acyl-CoA:cholesterol acyltransferase (ACAT)
Phospholipid Re-synthesis
- Lysophospholipids are re-acylated to form phospholipids in the SER
Lippincott Illustrated Reviews: Biochemistry 8e, Fig. 15.6
7. Step 6 - Chylomicron Assembly and Secretion
Chylomicron Composition
| Component | % of total |
|---|
| Triacylglycerol | ~86% |
| Phospholipid | ~7% |
| Cholesterol (free + ester) | ~5% |
| Protein (apolipoproteins) | ~2% |
Assembly Process
- Re-esterified TAG and cholesteryl esters are very hydrophobic and aggregate
- They are packaged as lipid droplets coated with:
- Phospholipids (outer monolayer)
- Free cholesterol
- Apolipoprotein B-48 (the structural apolipoprotein)
- Microsomal TG transfer protein (MTP/MTTP) is essential - transfers lipids onto Apo B-48 in the ER
- The particle moves through the Golgi where it is glycosylated
- Released by exocytosis from the basolateral surface of the enterocyte
Apo B-48
- Encoded by the same gene as Apo B-100 (the VLDL apolipoprotein in the liver)
- In the intestinal cell, the primary RNA transcript undergoes RNA editing: a stop codon is generated, producing a protein that is 48% of the size of the hepatic Apo B-100
- Hence the names "B-48" and "B-100"
Route of Chylomicrons
- Released into lacteals (lymphatic capillaries in intestinal villi)
- Lymph containing chylomicrons = chyle (milky appearance after a fat-rich meal)
- Travel via lymphatics → thoracic duct → left subclavian vein → systemic blood
- They are too large to pass through capillary endothelial cell junctions directly
Lippincott Illustrated Reviews: Biochemistry 8e, p. 503-504; Basic Medical Biochemistry 6e, p. 1061
8. Step 7 - Maturation of Chylomicrons in Blood
Nascent chylomicrons (just released from enterocytes) acquire additional proteins from HDL in lymph and blood:
- Apo E - recognized by liver membrane receptors (LDL receptors / remnant receptors) for endocytosis
- Apo C-II - activator of lipoprotein lipase (LPL)
This converts them into mature chylomicrons.
9. Step 8 - Chylomicron Metabolism in Peripheral Tissues
Lipoprotein Lipase (LPL)
- Located on the luminal surface of capillary endothelial cells, primarily in:
- Adipose tissue
- Skeletal and cardiac muscle
- Mammary gland (during lactation)
- Activated by Apo C-II
- Hydrolyzes TAG in chylomicrons → glycerol + FFA
- FFA are taken up by surrounding cells for:
- Energy (beta-oxidation) in muscle
- Re-esterification to TAG (storage) in adipose tissue
- Heparin releases LPL from endothelial cells (used clinically)
- Orlistat (anti-obesity drug): inhibits gastric and pancreatic lipases → reduces fat absorption
Chylomicron Remnants
- After TAG is removed by LPL, the depleted particle = chylomicron remnant
- Remnant still contains cholesterol, cholesteryl esters, Apo E, and some Apo C-II
- Apo C-II is returned to HDL
- Chylomicron remnants are taken up by the liver via Apo E-mediated endocytosis (binding to LDL receptor-related protein, LRP)
Basic Medical Biochemistry 6e, p. 1062
10. Absorption Site and Efficiency
| Lipid | Site of Maximal Absorption |
|---|
| Long-chain fatty acids | Upper jejunum (can extend to ileum) |
| Short/medium-chain FA | Stomach and upper small intestine |
| Cholesterol | Duodenum and jejunum |
| Fat-soluble vitamins | Duodenum and jejunum |
- On a moderate fat intake, 95% or more of ingested fat is absorbed
- During fasting, the enterocyte secretes VLDL (instead of chylomicrons) into lymphatics
Ganong's Review of Medical Physiology 26e, p. 487
11. Short-Chain Fatty Acids (SCFA) in the Colon
- Produced by bacterial fermentation of dietary fiber, resistant starch, and complex carbohydrates
- Average colonic concentration: ~80 mmol/L
- Composition: Acetate (~60%), Propionate (~25%), Butyrate (~15%)
- Absorbed via specific transporters (partly by exchange for H+)
- Provide energy (contribute to caloric intake)
- Butyrate is the preferred fuel for colonocytes
- Exert trophic effects on colonic epithelial cells and help combat inflammation
12. Lipid Malabsorption (Steatorrhea)
Steatorrhea = excess fat in the feces due to malabsorption. Common causes:
| Cause | Mechanism |
|---|
| Pancreatic insufficiency (CF, chronic pancreatitis) | Inadequate pancreatic lipase/colipase |
| Bile salt deficiency (liver disease, cholestasis, ileal resection) | Impaired micelle formation |
| Short bowel syndrome | Reduced absorptive surface |
| Celiac disease (villous atrophy) | Reduced mucosal absorptive area |
| Abetalipoproteinemia | Absent Apo B-48, chylomicrons cannot form |
| Bariatric surgery | Reduced pancreatic enzyme secretion |
Orlistat: inhibits gastric and pancreatic lipases → used as an anti-obesity drug; causes steatorrhea as a side effect.
13. Summary Flow Chart
Dietary TAG / Cholesterol Esters / Phospholipids
↓
STOMACH: Lingual + Gastric Lipase (acid lipases, pH 4-6)
Products: FFA (especially short/medium chain) + 1,2-DAG
↓
DUODENUM: Emulsification by bile salts + mechanical mixing
↓
PANCREATIC ENZYMES:
- Lipase + Colipase → 2-MAG + FFA (from TAG)
- Cholesterol esterase → Cholesterol + FFA
- PLA2 → Lysophospholipid + FFA
↓
MIXED MICELLE FORMATION (bile salts + lipid products)
↓
DIFFUSION through unstirred water layer to brush border
↓
ENTEROCYTE UPTAKE:
- SCFA/MCFA: direct absorption → portal blood
- LCFA: via diffusion/FATP → inside enterocyte
↓
INTRACELLULAR RE-ESTERIFICATION (in smooth ER):
- FFA + CoA → Acyl-CoA (fatty acyl-CoA synthetase)
- Acyl-CoA + 2-MAG → TAG (MGAT, DGAT)
- Cholesterol → Cholesteryl esters (ACAT)
↓
CHYLOMICRON ASSEMBLY (Apo B-48 + MTP, in ER → Golgi)
↓
EXOCYTOSIS from basolateral enterocyte → LACTEALS
↓
CHYLE → THORACIC DUCT → LEFT SUBCLAVIAN VEIN
↓
Nascent chylomicrons acquire Apo E + Apo C-II from HDL
↓
LPL (activated by Apo C-II) on capillary endothelium
→ TAG hydrolyzed → FFA taken up by muscle/adipose
↓
CHYLOMICRON REMNANTS → Liver (via Apo E / LRP receptor)
Key Biochemistry Points to Remember
| Concept | Key Fact |
|---|
| Pancreatic lipase specificity | Cleaves sn-1 and sn-3 bonds → leaves 2-MAG |
| Colipase | Zymogen (procolipase), activated by trypsin; 1:1 with lipase |
| Bile salts | Conjugated (glycine/taurine) amphipathic cholesterol derivatives |
| SCFA/MCFA | Portal route, no chylomicron needed |
| LCFA | Lymphatic/chylomicron route |
| Apo B-48 | RNA editing of Apo B-100 gene in intestine; structural protein of chylomicrons |
| MTP | Essential for chylomicron assembly; deficiency → abetalipoproteinemia |
| LPL activator | Apo C-II (transferred from HDL to chylomicrons) |
| Fat-soluble vitamins | Absorbed with LCFA from micelles; deficient if bile/pancreatic enzymes absent |
| Orlistat | Lipase inhibitor → anti-obesity drug → steatorrhea as side effect |
Sources:
- Lippincott Illustrated Reviews: Biochemistry, 8th ed. (Chapter 15)
- Basic Medical Biochemistry: A Clinical Approach, 6th ed. (Chapter 29)
- Ganong's Review of Medical Physiology, 26th ed. (Chapter 26)
- Medical Physiology (Boron & Boulpaep), Chapter 45